Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: Six African Countries To Produce mRNA Vaccines, CEPI Funds Indian Candidates

Executive Summary

Alvea, a US biotech startup, says its first two DNA vaccine candidates are undergoing “rigorous” preclinical testing and could enter clinical trials as early as April this year.

You may also be interested in...



Ukrainian Firm To Receive mRNA Tech Transfer From WHO Hub

The Ukrainian pharma firm Darnitsa, which is the latest firm to benefit from the WHO’s mRNA coronavirus vaccine initiative, says it is continuing production amidst the continuing Russian attacks on the country. Meanwhile, the European Medicines Agency has issued guidance for sponsors on methodological aspects of trials affected by the war.

WHO’s New Regulatory Benchmarking Framework To Go Live This Year

A new list of national regulators that want to be seen as meeting the highest international regulatory standards has been drawn up by the WHO in a drive to foster regulatory convergence and harmonization.

G20 Health Threats Fund Needs More Clout, WHO’s C-TAP Underused

Numerous initiatives are under way to maximize equitable access to COVID-19 products around the world, but most have some drawbacks that need to be addressed if they are to meet their goals, according to the medicines access NGO, WEMOS.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel